A regional and global assessment of priorities and challenges
Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches.
Despite its potential to make a significant impact on pharmaceutical care, digital health faces many challenges and concerns around the world. In hopes of identifying both the opportunities and challenges associated with integrating digital health into pharmaceutical patient care, with an emphasis on medication adherence and fighting substandard and falsified (SF) medicines, FIP-Global Pharmaceutical Observatory has launched a multinational needs assessment programme titled “How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges”.
About the programme:
The FIP Multi-national Education and Training Needs Assessment (FIP-METNA) project conducted in 2021, provided the foundation for future content and channel exploration to meet the needs of pharmacists’ education and address training gaps. Building on these outcomes, the FIP 2022 multinational needs assessment programme (MNAP), entitled “How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges” will culminate in a global roundtable and a summary report which will focus on supporting FIP members by assessing their needs.
About the regional events:
A series of six regional events aims to discuss the needs and challenges that nations and pharmaceutical leadership bodies face in using digital health to support medication adherence and combat SF medicines, as well as highlighting opportunities and ongoing initiatives in each region.
The programme will culminate with a summary report in which we will present the assessment of the challenges, limitations, and opportunities related to using digital health to support patient adherence, fighting SF medicines, and supporting other national pharmaceutical care services.